<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Jan. 8, 2020 (HealthDay News) — Starting antiretroviral therapy (ART) for HIV-infected infants within hours of birth does not seem to result in a higher proportion of infants who attain and sustain viral suppression on ART, according to a study published online Jan. 7 in EClinicalMedicine<\/i>.<\/p>\n
Louise Kuhn, Ph.D., from the Columbia University Irving Medical Center in New York City, and colleagues examined whether HIV-infected neonates who initiated ART <14 days after birth and were maintained on ART would be able to maintain viral suppression when ART was withdrawn. Seventy-three HIV-infected neonates were initiated on ART <14 days after birth and were maintained on ART.<\/p>\n
Overall, three HIV-infected infants died and nine were lost to follow-up before age 48 weeks. The researchers found that 52.5 percent of those surviving the study attained and sustained viral load <50 copies\/mL and half of these sustained CD4+ T cell percentage >30 percent, which were the eligibility criteria for an analytic treatment interruption trial. For the 46 infants starting ART <48 hours after birth and 27 infants starting at two to 14 days after birth, the differences in the proportions with achieved and sustained viral load <50 copies\/mL (51.4 and 53.9 percent, respectively) and sustained CD4+ T cell percentage >30 percent (45.7 and 38.5 percent, respectively) were not significantly different.<\/p>\n
“The results of our trial suggest that very early treatment in newborns may not have to mean within hours of birth,” Kuhn said in a statement. “Starting ART within the first two weeks of life led to similar outcomes to starting within the first two days of life.”<\/p>\n